Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 15/20 | 0.66 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1069436 | 0.91 | ZAP70 (0.65) | ZAP70JAK1MAP4K1EGFR | |
| SCHEMBL1047250 | 0.91 | ZAP70 (0.58) | ZAP70JAK1 | |
| SCHEMBL1049231 | 0.89 | ZAP70 (0.54) | ZAP70JAK1 | |
| SCHEMBL1046435 | 0.89 | ZAP70 (0.78) | ZAP70JAK1MAP4K1EGFR | |
| SCHEMBL27806221 | 0.87 | ZAP70 (0.55) | ZAP70EGFR | |
| SCHEMBL1082142 | 0.86 | ZAP70 (0.65) | ZAP70JAK1EGFR | |
| SCHEMBL1049153 | 0.84 | ZAP70 (0.66) | ZAP70JAK1MAP4K1EGFR | |
| SCHEMBL1047774 | 0.84 | ZAP70 (0.68) | ZAP70JAK1MAP4K1EGFR | |
| SCHEMBL1046635 | 0.83 | ZAP70 (0.70) | ZAP70JAK1MAP4K1EGFR | |
| SCHEMBL1047939 | 0.83 | ZAP70 (0.74) | ZAP70JAK1MAP4K1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| EP-2238137-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885JAK1 90/4885MAP4K1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.